RNA-binding protein biomarkers NR4A2 and NR4A3 in renal ischemia-reperfusion injury diagnosis

RNA结合蛋白生物标志物NR4A2和NR4A3在肾脏缺血再灌注损伤诊断中的应用

阅读:1

Abstract

BACKGROUND: The diagnosis of renal ischemia and reperfusion injury (RIRI) is crucial for renal transplant recipients. RNA-binding proteins (RBPs) may have an impact on disease development. Therefore, this study explored the biomarkers associated with RBPs in RIRI. METHODS: The RIRI related datasets, GSE37838 and GSE43974, and 3964 RBPs were employed in this research. The differential expression analysis was implemented for RIRI and control to gain differentially expressed genes in GSE37838. Then, differentially expressed genes were overlapped with RBPs to acquire intersection genes. Further, the machine learning, diagnostic analysis, and expression validation were executed to filtered biomarkers for RIRI. Additionally, pathway enrichment, molecular networks, and drug prediction were proceed. RESULTS: The area under the curve values of NR4A2 and NR4A3 were >0.7, as well as the expression trend was consistent in both datasets, and all of them were remarkably highly expressed in RIRI. Therefore, they were considered as biomarkers of RIRI. Enrichment analyses revealed that they were both associated with neuroactive ligand-receptor interactions, among others. Further, the lncRNA-miRNA-mRNA and transcription factors (TF)-mRNA network was constructed, revealing that they were all regulated by noncoding RNAs and TF, such as SNHG5-hsa-mir-10b-5p-NR4A3, CREB1, TFAP2A, etc. In addition, a large number of biomarker-related drugs were predicted, among which cadmium acetate, potassium chromate (VI), etc were associated with NR4A2 and NR4A3. CONCLUSION: In this study, we identified biomarkers associated with RBPs in RIRI, explored their associated pathways and drugs, which provided new insights into the clinical diagnosis and treatment of RIRI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。